Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 205

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 205
---
 between the Company and Armistice Capital Master Fund Ltd.

    10.6(7)
     
    Form of Securities Purchase Agreement dated February 9, 2023

    10.7(7)
     
    Form of Placement Agency Agreement Dated February 9, 2023

    10.8(8)
     
    Form of Securities Purchase Agreement dated February 1, 2024

    10.9(8)
     
    Form of Placement Agency Agreement dated February 1, 2024

    14.1(12)
     
    Code of Ethics

    14.2*
     
    Insider Trader Policy

    21.1(13)
     
    List of Subsidiaries.

    23.1*
     
    Consent of Baker Tilly US, LLP, independent registered public accounting firm of Revelation Biosciences, Inc.

    31.1*
     
    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    31.2*
     
    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 84

    32.1*
     
    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    32.2*
     
    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    97(14)
     
    Claw Back Policy

    99.1(12)
     
    Audit Committee Charter

    99.2(12)
     
    Compensation Committee Charter

    99.3(12)
     
    Nominating Committee Charter

    101.INS*
     
    XBRL Instance Document – the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.

    101.S